Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis
Saiju Jacob, Mahmoud Hashim, Brian Hutton, Kavita Gandhi, Suzy Van Sanden, Rafal Slowik, Christopher Drudge, Antoine C. El Khoury, Mi Jun Keng, Sumeet Singh, Sindhu Ramchandren, Nils Erik Gilhus
Springer Nature ·
2026-03-12
· DOI 10.1007/s12325-026-03543-1
The publisher did not provide an abstract — full text is available via the link below.
Saiju Jacob, Mahmoud Hashim, Brian Hutton, Kavita Gandhi, Suzy Van Sanden, Rafal Slowik et al. Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis. // Advances in Therapy. – 2026. – DOI: 10.1007/s12325-026-03543-1. – URL: https://doi.org/10.1007/s12325-026-03543-1
Saiju Jacob, Mahmoud Hashim, Brian Hutton, Kavita Gandhi, Suzy Van Sanden, Rafal Slowik, Christopher Drudge, Antoine C. El Khoury, Mi Jun Keng, Sumeet Singh, Sindhu Ramchandren, & Nils Erik Gilhus (2026). Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis. Advances in Therapy. https://doi.org/10.1007/s12325-026-03543-1
Saiju Jacob, et al. “Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis.” Advances in Therapy, 2026. doi:10.1007/s12325-026-03543-1.
@article{Jacob2026,
title = {Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis},
author = {Jacob, Saiju and Hashim, Mahmoud and Hutton, Brian and Gandhi, Kavita and Sanden, Suzy Van and Slowik, Rafal and Drudge, Christopher and Khoury, Antoine C. El and Keng, Mi Jun and Singh, Sumeet and Ramchandren, Sindhu and Gilhus, Nils Erik},
journal = {Advances in Therapy},
year = {2026},
doi = {10.1007/s12325-026-03543-1},
url = {https://doi.org/10.1007/s12325-026-03543-1}
}